What is Beximco Pharmaceuticals Cash Flow from Financing?
Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.
For the
three
months ended in Mar. 2024,
Beximco Pharmaceuticals paidBDT0 Mil more to buy back shares than it received from issuing new shares.
It spentBDT155 Mil paying down its debt.
It paidBDT0 Mil more to buy back preferred shares than it received from issuing preferred shares.
It spentBDT1,567 Mil paying cash dividends to shareholders.
It receivedBDT0 Mil on other financial activities.
In all, Beximco PharmaceuticalsspentBDT1,722 Mil on financial activities for the
three
months ended in Mar. 2024.
Beximco Pharmaceuticals Cash Flow from Financing Historical Data
The historical data trend for Beximco Pharmaceuticals's Cash Flow from Financing can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Beximco Pharmaceuticals Cash Flow from Financing Chart
Beximco Pharmaceuticals Cash Flow from Financing Calculation
This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.
Beximco Pharmaceuticals's Cash from Financing for the fiscal year that ended in Jun. 2023 is calculated as:
Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT-2,551 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (DHA:BXPHARMA) Cash Flow from Financing Explanation
Cash from financing contains six items:
1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.
Beximco Pharmaceuticals's issuance of stock for the
three
months ended in Mar. 2024 was BDT0 Mil.
2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.
Beximco Pharmaceuticals's repurchase of stock for the
three
months ended in Mar. 2024 was BDT0 Mil.
3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.
Beximco Pharmaceuticals's net issuance of debt for the
three
months ended in Mar. 2024 was BDT-155 Mil.
Beximco Pharmaceuticals spentBDT155 Mil paying down its debt.
4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.
Beximco Pharmaceuticals's net issuance of preferred for the
three
months ended in Mar. 2024 was BDT0 Mil.
Beximco Pharmaceuticals paidBDT0 Mil more to buy back preferred shares than it received from issuing preferred shares.
5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.
Beximco Pharmaceuticals's cash flow for dividends for the
three
months ended in Mar. 2024 was BDT-1,567 Mil.
Beximco Pharmaceuticals spentBDT1,567 Mil paying cash dividends to shareholders.
6. Other Financing:
Money spent or earned by company from other financial activities.
Beximco Pharmaceuticals's other financing for the
three
months ended in Mar. 2024 was BDT0 Mil.
Beximco Pharmaceuticals receivedBDT0 Mil on other financial activities.
Beximco Pharmaceuticals Cash Flow from Financing Related Terms
Thank you for viewing the detailed overview of Beximco Pharmaceuticals's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.
Beximco Pharmaceuticals (DHA:BXPHARMA) Business Description
Beximco Pharmaceuticals Ltd is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from local sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DHA:BXPHARMA has been successfully added to your 